Focuses on developing therapies for cardiovascular and metabolic diseases.
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company headquartered in Irvine, California, specializes in developing therapies for autoimmune diseases, amyotrophic lateral sclerosis (ALS), and conditions necessitating organ or cell-based transplants.
The company's primary focus is on advancing its lead product candidate, AT-1501, a humanized monoclonal antibody designed to target CD40 Ligand, a molecule expressed on T cells of the human immune system. AT-1501 is currently undergoing Phase 2a clinical trials for ALS treatment and Phase 2 clinical trials for islet cell transplantation in type 1 diabetes patients.
Formerly known as Novus Therapeutics, Inc., the company rebranded as Eledon Pharmaceuticals, Inc. in January 2021 to reflect its evolving therapeutic focus and strategic direction in the biopharmaceutical industry. Eledon Pharmaceuticals continues to drive innovation in autoimmune disease treatment and transplant medicine through ongoing research and development initiatives.